A detailed history of Royal Bank Of Canada transactions in Altimmune, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 37,119 shares of ALT stock, worth $298,807. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,119
Previous 31,012 19.69%
Holding current value
$298,807
Previous $206,000 10.19%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.5 - $8.1 $33,588 - $49,466
6,107 Added 19.69%
37,119 $227,000
Q2 2024

Aug 14, 2024

SELL
$5.91 - $10.23 $52,380 - $90,668
-8,863 Reduced 22.23%
31,012 $206,000
Q1 2024

Nov 05, 2024

BUY
$8.22 - $13.81 $72,853 - $122,398
8,863 Added 28.58%
39,875 $405,000
Q1 2024

May 15, 2024

SELL
$8.22 - $13.81 $429,215 - $721,102
-52,216 Reduced 56.7%
39,875 $405,000
Q4 2023

Feb 14, 2024

BUY
$2.14 - $11.62 $179,120 - $972,605
83,701 Added 997.63%
92,091 $1.04 Million
Q3 2023

Nov 14, 2023

SELL
$2.4 - $3.45 $25,555 - $36,735
-10,648 Reduced 55.93%
8,390 $21,000
Q2 2023

Aug 14, 2023

BUY
$3.45 - $5.97 $25,347 - $43,861
7,347 Added 62.84%
19,038 $67,000
Q1 2023

May 15, 2023

BUY
$4.19 - $16.83 $44,263 - $177,792
10,564 Added 937.36%
11,691 $49,000
Q4 2022

Feb 14, 2023

SELL
$8.74 - $16.45 $11,702 - $22,026
-1,339 Reduced 54.3%
1,127 $18,000
Q3 2022

Nov 14, 2022

SELL
$10.67 - $22.41 $62,174 - $130,583
-5,827 Reduced 70.26%
2,466 $31,000
Q2 2022

Aug 15, 2022

BUY
$3.94 - $11.77 $22,454 - $67,077
5,699 Added 219.7%
8,293 $97,000
Q1 2022

May 16, 2022

SELL
$5.9 - $9.45 $35,506 - $56,870
-6,018 Reduced 69.88%
2,594 $16,000
Q4 2021

Feb 14, 2022

BUY
$8.69 - $12.48 $18,622 - $26,744
2,143 Added 33.13%
8,612 $78,000
Q3 2021

Nov 15, 2021

BUY
$8.43 - $16.81 $20,923 - $41,722
2,482 Added 62.25%
6,469 $73,000
Q2 2021

Aug 16, 2021

BUY
$9.85 - $16.46 $39,271 - $65,626
3,987 New
3,987 $39,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $395M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.